Workflow
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
Spero TherapeuticsSpero Therapeutics(US:SPRO) GlobeNewswire News Roomยท2025-04-28 20:01

Core Viewpoint - Spero Therapeutics has appointed Esther Rajavelu as President and CEO, effective May 2, 2025, following her role as Interim President since January 2025, and she will also be nominated for the Board of Directors [1][2][3] Leadership Transition - Esther Rajavelu has been recognized for her leadership and focus on advancing Spero's programs and partnerships, particularly with GSK [2] - Rajavelu will continue her roles as Chief Financial Officer and Treasurer while succeeding Sath Shukla, who will step down from both his CEO position and the Board of Directors [3] Clinical Development Focus - The company is prioritizing the PIVOT-PO Phase 3 trial for tebipenem HBr, with an update expected this quarter [3] - The clinical program for tebipenem HBr is highlighted as the highest priority for Spero, indicating a strong commitment to advancing this treatment [3] Company Overview - Spero Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focusing on novel treatments for rare diseases and multi-drug resistant bacterial infections [4]